Navigation Links
CardioMEMS Completes CHAMPION Clinical Trial Study
Date:6/1/2010

ATLANTA, June 1 /PRNewswire/ -- The CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Patients) trial met its primary efficacy endpoint with a 30% reduction in heart failure hospitalization rates at 6 months (p<0.001) in heart failure patients whose treatment was guided by pulmonary artery pressures obtained through a tiny, permanent wireless implant.

The results were presented this week at the European Society of Cardiology Heart Failure Congress 2010 in Berlin, Germany, by the principal investigators of the trial:  William Abraham, M.D., Director of the Division of Cardiovascular Medicine at The Ohio State University Medical Center, and Philip Adamson, M.D., Director of the Heart Failure Institute at the Oklahoma Heart Hospital.  The study was sponsored by CardioMEMS, Inc., a medical technology company that has developed a novel wireless sensing and communication technology for the human body.

The CHAMPION trial evaluated the safety and effectiveness of the CardioMEMS heart failure (HF) pressure measurement system in New York Heart Association Class III (NYHA Class III) heart failure patients; these patients experience symptoms of heart failure with only mild exertion. NYHA Class III represents roughly 1.5 million of the six million heart failure patients in the U.S., and historically accounts for nearly half of all heart failure hospitalizations.

The CHAMPION Trial enrolled 550 patients, who had been hospitalized for heart failure in the previous year, at 63 leading heart centers in the U.S.  All subjects received the CardioMEMS CHAMPION HF sensor as a permanent pulmon
'/>"/>

SOURCE CardioMEMS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... MISSION, Kan. , July 25, 2014 /PRNewswire-iReach/ ... , and TCGRx, of Powers Lake, ... exclusive partners in a distribution and co-marketing agreement ... to retail pharmacies throughout the United ... of robotics-based pharmacy management and workflow systems to ...
(Date:7/25/2014)... GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased to ... with LaurelCo, LLC, an Illinois limited ... and dispensary medical marijuana licenses in the state of ... acquire a 20% equity interest in LaurelCo, LLC in exchange ... chambers, as well as all technology related to the machines ...
(Date:7/25/2014)... 25, 2014  Acsis Inc., the market leader ... solutions, has recently posted an article, "Future ... and future needs for companies, extended supply chain, ... chain model no longer work today.  The article ... growth of mobile technology, machine to machine (M2M) ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Acsis Addresses Questions on the Modern Supply Chain 2
... 17 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) ... Oxygen Concentrate Gel to customers who have pre-ordered through ... today, cover orders received through early November. , "This ... actually shipping a product to customers and generating revenue ...
... , REYKJAVIK, Iceland, Nov. 17 deCODE ... has filed a voluntary petition for relief under Chapter 11 ... Bankruptcy Court for the District of Delaware to facilitate the ... to operate its business and manage its properties as a ...
Cached Medicine Technology:Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 2deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 3deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 4
(Date:7/25/2014)... Angeles, CA (PRWEB) July 25, 2014 In ... talk about, and eager to reverse the symptoms associated with ... in the media at large, a new case study ... real benefits of testosterone therapy using bioidentical hormones. ... a 38-year-old father from Seattle who found himself beginning to ...
(Date:7/25/2014)... As reported by the New Orleans Advocate ... (7/3), the state of Louisiana has recently seen a ... than cocaine. Officials believe the increase is due to a ... of marijuana. However, both doctors and police confirm that that ... to call it “poison,” doctors have acknowledged that the Louisiana ...
(Date:7/25/2014)... 2014 Sport Court® provided ... Nike National Invitational Tournament (NIT) in Chicago ... Junior National Tournament (USJN) in Washington D.C. at ... for these prestigious national tournaments included 44 Sport Court ... of playing surface at McCormick Place for the NIT, ...
(Date:7/25/2014)... Houston, TX (PRWEB) July 25, 2014 ... Annual Family Fun Fest on Sunday, July 27 at ... franchises include Memorial, Copperfield, Katy, Pearland, Friendswood, Spring, ... location in The Heights. , “We’re thrilled to ... this year,” said Heather Belcher who owns the Sugarland-Missouri ...
(Date:7/25/2014)... July 25, 2014 A new study conducted ... revealed that 39 percent of all children in the survey under ... The survey looked at 2,505 children during the years of 2011 ... years of age. The final result was that about two ... Many of these children were from lower-income families and were of ...
Breaking Medicine News(10 mins):Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... UCSF institute aimed at accelerating the pace of translating ... million from the National Institutes of Health to expand ... UCSF Clinical and Translational Science Institute (CTSI) is among ... recognition of their successes during the first five years ...
... HealthDay Reporter , MONDAY, July 18 (HealthDay News) -- ... of mild cognitive impairment, a potential precursor of Alzheimer,s ... there may be a very high rate of cognitive ... general population in that age range," said lead researcher ...
... , FRIDAY, July 15 (HealthDay News) -- Although many people ... relationship between stress and alcohol is a two-way street, researchers ... stress, the authors of a new study pointed out. Meanwhile, ... individuals to drink more to produce the same effect. As ...
... (HealthDay News) -- Compared with older people with no signs of ... twice as likely to experience a fall, researchers have found. ... older adults who were participating in a study of memory and ... many times they fell over the course of eight months. ...
... 2011) Today at the 6th International AIDS ... Prevention, the Drugs for Neglected Diseases initiative (DNDi) ... programme to address critical unmet treatment needs of ... in young children has largely been eliminated in ...
... York University,s Department of Chemistry and NYU Langone Medical ... a protein implicated in many types of cancer. The ... journal Nature Chemical Biology. The ... RTK signaling is a major underlying cause of various ...
Cached Medicine News:Health News:UCSF receives $112 million to help translate science into cures 2Health News:UCSF receives $112 million to help translate science into cures 3Health News:UCSF receives $112 million to help translate science into cures 4Health News:Ex-NFL Players May Face Higher Brain Damage Risk, Study Says 2Health News:Ex-NFL Players May Face Higher Brain Damage Risk, Study Says 3Health News:Ex-NFL Players May Face Higher Brain Damage Risk, Study Says 4Health News: Drinking Alcohol May Prolong, Not Relieve, Stress 2Health News:Falls Could Signal Early Alzheimer's Disease 2Health News:DNDi launches new drug development program to address treatment needs of children with HIV/AIDS 2Health News:DNDi launches new drug development program to address treatment needs of children with HIV/AIDS 3
... integrates drug infusion,with patient monitoring and ... modular platform. With multiple configuration,options, you ... you,need them, keeping the number of ... while managing the unique needs of,each ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
... the first steps any hospital or health ... most powerful, most effective tools available for ... world-class clinician documentation and electronic medical record ... achieve this goal. In fact, its the ...
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
Medicine Products: